The drugmakers had argued that their alleged use of a patented fluorescent protein to identify COVID-19 antibodies is protected by a safe harbor provision that covers the FDA approval process. Troutman Pepper lawyers persuaded U.S. District Judge Marilyn Huff that the safe harbor provision should not apply, at least not at this early stage of litigation.
May 05, 2021 at 12:17 PM
1 minute read
The original version of this story was published on The Recorder
A San Diego biotech company has moved a step closer to claiming a share of Pfizer Inc. and BioNTech SE’s COVID-19 vaccine profits.
Presented by BigVoodoo
General Counsel Summit is the premier event for in-house counsel, hosting esteemed legal minds from all sectors of the economy.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
WIPL is the original global forum facilitating women-to-women exchange on leadership and legal issues.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Predictive reporting, trend analysis, peer guidance and a practical playbook to help genetal counsels succeed in their increasingly high stakes roles as risk managers and corporate strategists
People wait in line to enter the mass vaccination site at M&T Bank Stadium and receive the Pfizer vaccine in Baltimore, on April 7, 2021. Photo: Diego M. Radzinschi/ALM
